AB-FUBINACA

AB-FUBINACA is a highly potent synthetic cannabinoid that acts as a strong full agonist for human cannabinoid receptors. Originally patented by Pfizer in 2009 for potential therapeutic use, it was never approved for humans and is now classified as an illegal controlled substance globally due to its severe health risks.

Origins and History

- Pharmaceutical Origin: Developed by Pfizer as an analgesic medication, but never pursued for human medical or commercial applications.
- Designer Drug Market: First detected in Japan in 2012 as an unregulated ingredient in synthetic “herbal incense” or “Spice” blends.
- Current Status: It is heavily restricted and monitored internationally. It is a Schedule I substance in the United States and a Class B drug in the UK. [1, 2, 3, 4]

Pharmacology and Effects

Unlike naturally occurring THC (which is a partial agonist), AB-FUBINACA is a full agonist, meaning it binds with extreme affinity and drives a much more intense response from the brain’s CB1 receptors. [1, 2]

Physiological Effects: Produces classical “cannabimimetic” effects such as catalepsy, extreme hypothermia (lowered body temperature), and suppressed locomotor activity.
Short Duration: It features a very rapid onset but shorter duration of action than natural THC.

AB-FUBINACA

Product Guarantees

Need technical specifications?

Need a larger quantity or custom grade?